3.21
price up icon2.88%   0.09
after-market Dopo l'orario di chiusura: 3.21
loading
Precedente Chiudi:
$3.12
Aprire:
$3.12
Volume 24 ore:
445.10K
Relative Volume:
0.69
Capitalizzazione di mercato:
$736.26M
Reddito:
$596.48M
Utile/perdita netta:
$123.72M
Rapporto P/E:
5.8534
EPS:
0.5484
Flusso di cassa netto:
$106.59M
1 W Prestazione:
-1.83%
1M Prestazione:
+11.07%
6M Prestazione:
+15.88%
1 anno Prestazione:
+31.56%
Intervallo 1D:
Value
$3.06
$3.24
Intervallo di 1 settimana:
Value
$3.045
$3.29
Portata 52W:
Value
$2.215
$5.28

Curevac N V Stock (CVAC) Company Profile

Name
Nome
Curevac N V
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
1,088
Name
Cinguettio
Name
Prossima data di guadagno
2025-04-10
Name
Ultimi documenti SEC
Name
CVAC's Discussions on Twitter

Confronta CVAC con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CVAC
Curevac N V
3.21 736.26M 596.48M 123.72M 106.59M 0.5484
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Curevac N V Stock (CVAC) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-04-25 Downgrade Leerink Partners Outperform → Market Perform
2023-06-08 Iniziato SVB Securities Outperform
2023-01-19 Aggiornamento UBS Neutral → Buy
2023-01-09 Aggiornamento Jefferies Hold → Buy
2022-01-21 Downgrade BofA Securities Neutral → Underperform
2022-01-18 Iniziato JMP Securities Mkt Outperform
2021-10-22 Iniziato Deutsche Bank Hold
2021-06-17 Downgrade BofA Securities Buy → Neutral
2021-04-26 Ripresa Credit Suisse Underperform
2021-04-26 Iniziato Guggenheim Neutral
2020-12-10 Downgrade Credit Suisse Neutral → Underperform
2020-09-08 Iniziato BofA Securities Buy
2020-09-08 Iniziato Credit Suisse Neutral
2020-09-08 Iniziato Jefferies Hold
Mostra tutto

Curevac N V Borsa (CVAC) Ultime notizie

pulisher
Apr 14, 2025

CureVac Among 3 Promising Penny Stocks To Watch - Yahoo Finance

Apr 14, 2025
pulisher
Apr 13, 2025

CureVac (NASDAQ:CVAC) Trading Up 7.5% – Should You Buy? - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Call Transcript - Insider Monkey

Apr 12, 2025
pulisher
Apr 11, 2025

CureVac N.V. Earnings Call: Financial Strength Amid Challenges - TipRanks

Apr 11, 2025
pulisher
Apr 11, 2025

CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode - MSN

Apr 11, 2025
pulisher
Apr 11, 2025

CureVac NV earnings beat by €0.06, revenue topped estimates - Investing.com South Africa

Apr 11, 2025
pulisher
Apr 11, 2025

CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com

Apr 11, 2025
pulisher
Apr 11, 2025

CureVac: 2025 will be less costly - marketscreener.com

Apr 11, 2025
pulisher
Apr 11, 2025

CureVac Announces Financial Results for the Fourth Quarter and F - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience - Yahoo Finance

Apr 11, 2025
pulisher
Apr 11, 2025

CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience By GuruFocus - Investing.com Canada

Apr 11, 2025
pulisher
Apr 11, 2025

CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Pa - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

CureVac Reports Strong 2024 Financial Results and Strategic Progress - TipRanks

Apr 10, 2025
pulisher
Apr 10, 2025

CureVac Reports 2024 Financial Results and Strategic Advances - TipRanks

Apr 10, 2025
pulisher
Apr 10, 2025

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update - ACCESS Newswire

Apr 10, 2025
pulisher
Apr 10, 2025

CureVac Q4 2024 Earnings Call Transcript - MarketBeat

Apr 10, 2025
pulisher
Apr 09, 2025

Insights Ahead: CureVac's Quarterly Earnings - Benzinga

Apr 09, 2025
pulisher
Apr 09, 2025

CureVac to initiate Phase 1 trial for its lung cancer therapy - MSN

Apr 09, 2025
pulisher
Apr 08, 2025

FDA clears CureVac’s IND application for Phase I lung cancer trial - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

FDA clears Curevac’s IND for CVHNLC - BioWorld MedTech

Apr 08, 2025
pulisher
Apr 08, 2025

EQS-News: CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - sharewise.com

Apr 08, 2025
pulisher
Apr 08, 2025

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 08, 2025

CureVac Financial Results: Key mRNA Biotech Player to Reveal 2024 Performance - Stock Titan

Apr 08, 2025
pulisher
Apr 07, 2025

CureVac’s lung cancer therapy clears FDA hurdle - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

CureVac’s lung cancer therapy clears FDA hurdle By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

CureVac's Early-stage Trial of Lung Cancer Drug Gets US FDA Clearance - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

CureVac to initiate Phase 1 trial for its lung cancer therapy (CVAC:NASDAQ) - Seeking Alpha

Apr 07, 2025
pulisher
Apr 07, 2025

CureVac Receives FDA Clearance to Initiate Phase 1 Trial of Lung Cancer Therapy - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

EQS-News: CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer - sharewise.com

Apr 07, 2025
pulisher
Apr 07, 2025

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer - ACCESS Newswire

Apr 07, 2025
pulisher
Apr 05, 2025

CureVac N.V.'s (NASDAQ:CVAC) Profit Outlook - simplywall.st

Apr 05, 2025
pulisher
Apr 02, 2025

CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

Is CureVac (CVAC) the Best German Stock to Buy According to Hedge Funds? - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 01, 2025

CureVac (NASDAQ:CVAC) Stock Price Down 7.2%What's Next? - MarketBeat

Apr 01, 2025
pulisher
Mar 28, 2025

CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions (NASDAQ:CVAC) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

CureVac (CVAC) Stock Surges After Favorable Patent Ruling - Stocks Telegraph

Mar 28, 2025
pulisher
Mar 28, 2025

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

Lululemon, General Motors and Apple fall premarket; CureVac gains By Investing.com - Investing.com Canada

Mar 28, 2025
pulisher
Mar 28, 2025

Lululemon, General Motors and Apple fall premarket; CureVac gains - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

CureVac, gold miners, Rocket Lab - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

CureVac Patent Validated in BioNTech Dispute, Infringement Hearing Set for July - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

PRTG Soars On Mesothelioma Data, NVNO Awaits FDA Decision, CureVac Jumps On Patent News - RTTNews

Mar 28, 2025
pulisher
Mar 27, 2025

CureVac’s amended patent upheld by European Patent Office By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

European Patent Office declares CureVac mRNA patent valid - Marketscreener.com

Mar 27, 2025

Curevac N V Azioni (CVAC) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Capitalizzazione:     |  Volume (24 ore):